LUPIN2,074.00

Lupin Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹94,823 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations5,038.65,197.44,960.85,600.35,672.75,767.75,667.16,268.37,047.57,167.57,474.78,276.9
Other Income40.429.429.367.842.353.757.079.090.0114.7140.7130.3
Total Income5,079.05,226.84,990.05,668.15,715.05,821.45,724.16,347.47,137.57,282.27,615.48,407.2
Expenses
+ Cost of Materials Consumed991.01,106.71,094.41,145.71,118.11,084.11,109.51,126.61,139.21,124.81,231.31,311.7
+ Purchases of Stock-in-Trade854.7676.1661.1640.6660.0766.4575.7714.0724.9719.7708.4842.3
+ Changes in Inventories-143.0-56.8-181.7-41.7-88.2-128.91.1-68.7-39.333.6-88.1-64.7
+ Employee Benefit Expense860.7889.2900.2971.01,007.5984.41,001.31,083.01,105.61,143.31,242.71,383.0
+ Finance Costs80.674.071.368.070.966.989.191.8107.6115.0120.2109.6
+ Depreciation & Amortisation247.9257.2457.1247.7256.9271.5393.2299.0316.8313.0446.8452.9
+ Other Expenses1,557.31,544.21,489.91,643.81,634.91,705.91,658.51,686.21,775.91,884.31,894.82,355.1
Total Expenses4,449.34,490.74,492.34,675.14,660.24,750.24,828.24,931.85,130.55,333.65,556.06,389.8
EBITDA917.81,037.9996.91,241.01,340.41,355.91,321.21,727.22,341.32,261.92,485.62,449.6
EBIT669.9780.7539.8993.31,083.41,084.5928.01,428.32,024.61,948.92,038.81,996.7
Profit
PBT before Exceptional Items629.7736.1497.7993.01,054.91,071.3895.81,415.52,007.01,948.62,059.32,017.4
+ Exceptional Items0.00.00.00.00.00.00.00.00.0-426.6-131.30.0
Pretax Income629.7736.1497.7993.01,054.91,071.3895.81,415.52,007.01,522.01,928.02,017.4
+ Current Tax172.3225.5106.0237.6202.9269.1281.1490.9324.0204.6507.9984.4
+ Deferred Tax-38.0-108.123.5-50.1-7.6-56.7-167.7-296.8198.2137.0-48.6-384.0
Tax Expense134.4117.4129.5187.5195.4212.4113.5194.1522.1341.5459.3600.4
+ Share of Associates & JVs0.00.00.00.00.00.00.00.00.00.00.0-0.0
Net Income495.3618.7368.2805.5859.5858.9782.41,221.51,484.81,180.51,468.71,417.0
+ Net Income — Continuing Ops495.3618.7368.2805.5859.5858.9782.41,221.51,484.81,180.51,468.71,417.0
+ Other Comprehensive Income22.478.2-27.1-52.757.7-119.523.0160.295.8120.164.335.5
Total Comprehensive Income517.7696.9341.1752.9917.2739.3805.41,381.71,580.71,300.61,532.91,452.5
Net Income to Common489.7613.1359.4801.3852.6855.2772.51,219.01,477.91,175.61,460.31,415.0
Minority Interest5.75.68.84.26.93.79.92.46.95.08.32.0
Per Share
Basic EPS10.7613.477.8917.5818.7018.7516.9326.7032.3625.7431.9630.95
Diluted EPS10.7213.417.8617.5218.6418.6916.8726.6232.2825.6731.8930.89
Other Comprehensive Income — detail
+ Other Comprehensive Income23.0160.295.8120.164.335.5
+ Items NOT to be Reclassified to P&L-1.4-10.45.1-10.5-11.116.0-17.8-10.49.4-5.90.5-0.1
+ Tax on Items NOT to be Reclassified-6.4-3.64.3-2.71.9-0.1
+ Tax on Items NOT to be Reclassified — alt tag-0.5-2.50.8-3.7-3.96.0
+ Items to be Reclassified to P&L22.886.4-30.9-36.364.9-129.534.4169.575.4122.951.852.2
+ Tax on Items to be Reclassified0.02.5-15.3-0.5-13.916.7
+ Tax on Items to be Reclassified — alt tag-0.50.30.59.60.00.0
Comprehensive Income — Owners of Parent23.276.4-25.9-49.2906.6736.6794.91,377.31,573.51,295.71,522.01,451.1
Comprehensive Income — Non-controlling Interests-0.81.7-1.2-3.510.52.710.64.47.24.911.01.4
Per Share — as-filed variants
Basic EPS — Continuing Operations10.7613.477.8917.5818.7018.7516.9326.7032.3625.7431.9630.95
Diluted EPS — Continuing Operations10.7213.417.8617.5218.6418.6916.8726.6232.2825.6731.8930.89
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit3,335.83,471.33,387.03,855.83,982.84,046.23,980.94,496.45,222.75,289.45,623.06,187.7
Gross Margin %66.2166.7968.2768.8570.2170.1570.2571.7374.1173.8075.2374.76
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)629.7736.1497.7993.01,054.91,071.3895.81,415.52,007.01,948.62,059.32,017.4
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.00.00.0-426.6-131.30.0
Net Income Adj (tax-effected)495.3618.7368.2805.5859.5858.9782.41,221.51,484.81,511.41,568.71,417.0
EPS Adj10.7613.477.8917.5818.7018.7516.9326.7032.3632.9534.1430.95
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital91.191.191.191.291.291.391.391.491.491.491.491.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.